Targeting of CD34(+)CD38(-) cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia

BACKGROUND: The CD34(+)CD38(-) subset of AML cells is enriched for resistance to current chemotherapeutic agents and considered to contribute to disease progression and relapse in Acute Myeloid Leukaemia (AML) patients following initial treatment. METHODS: Chemosensitivity in phenotypically defined...

Descripción completa

Detalles Bibliográficos
Autores principales: Jawad, Mays, Yu, Ning, Seedhouse, Claire, Tandon, Karuna, Russell, Nigel H, Pallis, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488582/
https://www.ncbi.nlm.nih.gov/pubmed/23013471
http://dx.doi.org/10.1186/1471-2407-12-431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488582/
https://www.ncbi.nlm.nih.gov/pubmed/23013471
http://dx.doi.org/10.1186/1471-2407-12-431

Ejemplares similares